Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)
Qaseem, Amir Yost, Jennifer Etxeandia-Ikobaltzeta, Itziar Abraham, George M Jokela, Janet A. Forciea, Mary Ann Miller, Matthew C. Humphrey, Linda L.
Qaseem, Amir
Yost, Jennifer
Etxeandia-Ikobaltzeta, Itziar
Abraham, George M
Jokela, Janet A.
Forciea, Mary Ann
Miller, Matthew C.
Humphrey, Linda L.
Citations
Altmetric:
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Journal Article
Publication Date
2021-02-09
Subject Area
Collections
Embargo Expiration Date
Link to Full Text
Abstract
Practice points for clinicians developed by the American College of Physicians addressing these questions: What are the effectiveness and harms of remdesivir in hospitalized patients with coronavirus disease 2019 (COVID-19)? Do effectiveness and harms in hospitalized patients with COVID-19 vary by symptom duration, disease severity, and treatment duration?
Source
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2021 Feb 9. doi: 10.7326/M20-8101. Epub ahead of print. PMID: 33560862. Link to article on publisher's site
Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.7326/M20-8101
Permanent Link to this Item
PubMed ID
33560862